HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO BlissBio - The Pipeline Has Not yet Been Verified as No Deal Has Been Reached with MNCs

Pre-IPO Vigonvita Life Sciences (PHIP Updates) - Some Points Worth the Attention

Pre-IPO LXJ International Holdings - The Pain Points and the Outlook

China Healthcare Weekly (Oct.13)-Genor to Acquire Edding, RemeGen's Bleak Outlook, Zai Lab's Trouble

Chagee Holdings - Thoughts on the IPO Debut and the Valuation Outlook

Pre-IPO Chagee Holdings - IPO Pricing Is Attractive, But Share Price May Underperform

Equity Capital Markets

Genor Biopharma Holdings  / Equity Capital Markets

<ul>
<li>The merger is good for both parties. On the one hand, it helps boost Genor's valuation. On the other hand, it finally makes Edding realize its desire to go public.</li>
<li>The outlook of Edding Genor Group depends on the pipeline quality. Core products Vancocin/Ceclor/FPN are facing different challenges. The pipeline strength/R&amp;D capabilities of Genor hasn’t been recognized by the market.</li>
<li>Short-Term valuation is expected to reach RMB7.5 billion. Future valuation could be above RMB10 billion if pipeline R&amp;D progress/clinical data and the commercialization performance of marketed products meet the expectation.</li>
</ul>


The merger is good for both parties. On the one hand, it helps boost Genor's valuation. On the other hand, it finally makes Edding realize its desire to go public.
The outlook of Edding Genor Group depends on the pipeline quality. Core products Vancocin/Ceclor/FPN are facing different challenges. The pipeline strength/R&amp;D capabilities of Genor hasn’t been recognized by the market.
Short-Term valuation is expected to reach RMB7.5 billion. Future valuation could be above RMB10 billion if pipeline R&amp;D progress/clinical data and the commercialization performance of marketed products meet the expectation.


Shanghai Fosun Pharmaceutical (Group) (2196 HK)

Genor Biopharma (6998 HK) - The Reverse Merger Will Unleash the Upside Potential of Valuation